COPD Treatments- MPR

COPD Treatments

COPD TREATMENTS
Generic	Brand	Form	Usual Dosage
BRONCHODILATORS
Long-Acting Beta₂‑Agonists (LABAs)
arformoterol	Brovana*	soln	Adults: Inhale 15mcg twice daily (AM & PM) by nebulization (max: 30mcg/day). Use standard jet nebulizer with air compressor (see full labeling). Children: Not established.
formoterol	Perforomist*	soln	Adults: Inhale one 20mcg vial twice daily (AM & PM) by nebulization (max: 40mcg/day). Use standard jet nebulizer and air compressor. Children: Not established.
olodaterol	Striverdi Respimat*	MDI	Adults: 2 inh once daily; max 2 inh/24hrs Children: Not established.
salmeterol	Serevent Diskus*	DPI	Adults: 1 inh (50mcg) twice daily (approx. 12hrs apart) Children: Not established.
Short-Acting Anticholinergics
ipratropium bromide	—	soln	Adults: 500mcg by oral nebulization 3−4 times daily every 6−8hrs Children: Not established.
ipratropium bromide	Atrovent HFA	MDI	Adults: 2 inh 4 times daily; max 12 inh/24hrs Children: Not established.
Long-Acting Anticholinergics
aclidinium bromide	Tudorza Pressair	DPI	Adults: 1 inh (400mcg) twice daily (approx. 12hrs apart) Children: Not established.
glycopyrrolate	Lonhala Magnair*	soln	Adults: 1 oral inh of one 25mcg vial twice daily (AM & PM); max 2 inh/24hrs. Only use with Magnair device. Children: Not established.
revefenacin	Yupelri*	soln	Adults: 1 oral inh of one 175mcg vial once daily using a mouthpiece. Use standard jet nebulizer with air compressor. Children: Not established.
tiotropium bromide	Spiriva HandiHaler	caps	Adults: 2 inh of one 18mcg cap once daily, using HandiHaler device. Max: 2 inh/24hrs. Children: Not established.
tiotropium bromide	Spiriva Respimat	MDI	Adults: 2 inh of 2.5mcg/actuation (5mcg) once daily; max: 2 inh/24hrs Children: Not established.
umeclidinium	Incruse Ellipta*	DPI	Adults: 1 inh once daily; max 1 inh/24hrs Children: Not established.
Anticholinergic + Beta₂‑Agonist
ipratropium bromide + albuterol	—	soln	Adults: 1 vial 4−6 times daily via nebulizer Children: Not established.
ipratropium bromide + albuterol	Combivent Respimat	MDI	Adults: 1 inh 4 times daily; max 6 inh/24hrs Children: Not established.
Anticholinergic + Long-Acting Beta₂‑Agonist (LABA)
aclidinium bromide/ formoterol	Duaklir Pressair*	DPI	Adults: 1 inh twice daily (AM & PM); max 1 inh twice daily Children: Not established.
glycopyrrolate + formoterol	Bevespi Aerosphere*	MDI	Adults: 2 inh twice daily (AM & PM); max 2 inh twice daily Children: Not established.
tiotropium + olodaterol	Stiolto Respimat*	MDI	Adults: 2 inh once daily; max 2 inh/24hrs Children: Not established.
umeclidinium + vilanterol	Anoro Ellipta*	DPI	Adults: 1 inh once daily; max 1 inh/24hrs Children: Not established.
CORTICOSTEROIDS
Corticosteroid + Long-Acting Beta₂-Agonist (LABA)
budesonide + formoterol	Symbicort 160/4.5*	MDI	Adults: 2 inh of 160/4.5mcg twice daily (approx. 12hrs apart) Children: Not indicated.
fluticasone propionate + salmeterol	Advair 250/50 Diskus*	DPI	Adults: 1 inh of 250/50mcg twice daily (approx. 12hrs apart) Children: Not established.
fluticasone propionate + salmeterol	Wixela Inhub*	DPI	Adults: 1 inh of 250/50mcg twice daily (approx. 12hrs apart) Children: Not established.
fluticasone furoate + vilanterol	Breo Ellipta*	DPI	Adults: 1 inh of 100/25mcg once daily; max 1 inh/24hrs Children: Not established.
Corticosteroid + Anticholinergic + Long-Acting Beta₂-Agonist (LABA)
budesonide + glycopyrrolate + formoterol	Breztri Aerosphere*	MDI	Adults: 2 inh twice daily (AM & PM); max 2 inh twice daily Children: Not established.
fluticasone furoate + umeclidinium + vilanterol	Trelegy Ellipta*	DPI	Adults: 1 inh of 100/62.5/25mcg once daily; max 1 inh/24hrs Children: Not established.
OTHER
PDE4-Inhibitor
roflumilast	Daliresp	tabs	Adults: 500mcg once daily. Initiating 250mcg daily for 4wks, then increasing to 500mcg may reduce the rate of discontinuation in some patients. Children: Not established.
NOTES
Key: DPI = dry powder inhaler; MDI = metered dose inhaler *Not indicated to treat acute deteriorations of COPD. Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 12/2022)

Want to read more?